Xin Lang Zheng Quan·2025-08-31 10:46Core Viewpoint - New Mile Health Technology Group reported a revenue of 1.588 billion yuan in the first half of 2025, reflecting a year-on-year decline of 20.63%, while implementing effective cost control measures to navigate industry challenges [2][4]. Financial Performance - The company achieved a revenue of 1.588 billion yuan in H1 2025, with the medical services segment contributing 1.38 billion yuan and the pharmaceutical segment 210 million yuan [2]. - Gross margin stood at 28.2%, with the medical services segment at 26% and the pharmaceutical segment at 40.47% [2]. - Pre-tax operating profit was 33.73 million yuan, and net profit attributable to shareholders was 7.43 million yuan [2]. - Operating cash flow was 140 million yuan, down 15% year-on-year, but the decline was less than that of revenue and profit [2]. Cost Control Measures - The drug cost ratio in the medical services segment was 24.10%, down 2.29 percentage points year-on-year, while the cost of consumables was 12.81%, down 0.91 percentage points [3]. - Overall variable cost ratios have been decreasing, indicating effective cost management [3]. Drug Procurement and Reimbursement - The company has actively managed drug cost ratios in response to medical insurance policies, achieving a 3.3 percentage point decrease in the first half of 2025 [4]. - As of H1 2025, the proportion of drug procurement through centralized purchasing was approximately 23% of total drug costs [4]. - Medical insurance revenue accounted for about 50.5% of total revenue, with stable reimbursement timelines [4]. Hospital Development and Service Expansion - The company is enhancing its hospital discipline layout and has made significant progress in hospital grading, with several hospitals achieving higher levels of accreditation [5]. - New bed expansions are underway, with multiple hospitals adding significant capacity [5]. Market Outlook and Strategic Initiatives - Following the implementation of centralized procurement policies, sales volumes are expected to recover and exceed last year's figures in the second half of 2025 [7]. - The company plans to adapt to ongoing medical insurance reforms and leverage opportunities in the aging economy, focusing on a dual-driven strategy of "medical + pharmaceutical" and "medical + insurance" [7].